On October 11, 2021, ReNeuron Group plc (AIM: RENE), a global leader in the development of exosome therapeutics, announced positive data that provides clear pre-clinical proof-of-concept that ReNeuron’s novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases. In an ongoing collaboration with scientists at the University of Salamanca, Spain, ReNeuron has sought to determine whether its stem cell-derived exosomes can deliver a therapeutic protein to the corpus striatum; a region of the brain affected by disabling neurological diseases such as stroke, Parkinson’s disease, and Huntington’s disease. Major pharmaceutical companies have identified therapeutic proteins that are effective in treating a variety of neurological diseases. However, there are major issues associated with the delivery of these protein therapeutics, which include the poor stability in living organisms, given that proteins rapidly break down and do not last long in the body; as well as issues surrounding poor tissue distribution due to an inability to target specific tissues. Whilst these issues cannot be overcome by simply administering more protein, as this can have unwanted side-effects, ReNeuron believes that its proprietary exosomes have the potential to address both these issues due to their natural tissue-targeting ability and superior stability characteristics.
Login Or Register To Read Full Story